Toggle Main Menu Toggle Search

Open Access padlockePrints

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities

Lookup NU author(s): Professor Martin NobleORCiD, Professor Jane Endicott

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2-anilinopyrimidine derivatives with functional groups attached to the CS-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,(34) provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B-and T-cells.


Publication metadata

Author(s): Shao H, Shi SH, Huang SL, Hole AJ, Abbas AY, Baumli S, Liu XR, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang SD

Publication type: Article

Publication status: Published

Journal: Journal of Medicinal Chemistry

Year: 2013

Volume: 56

Issue: 3

Pages: 640-659

Print publication date: 09/01/2013

ISSN (print): 0022-2623

ISSN (electronic): 1520-4804

Publisher: American Chemical Society

URL: http://dx.doi.org/10.1021/jm301475f

DOI: 10.1021/jm301475f


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
C21568/A8988Cancer Research UK
C21568/A12474Cancer Research UK

Share